Neoplasms

Digestive System Diseases

Gland and Hormone Related Diseases

All Conditions

Symptoms and General Pathology

Nutritional and Metabolic Diseases

Nervous System Diseases

Rare Diseases

Pancreatic Neoplasms

Cancer Pain

Pain

Celiac Disease

Pain, Intractable

Gastrointestinal Diseases

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Pancreatic Diseases

Endocrine System Diseases

Neurologic Manifestations

Pancreatic Cancer

Central Nervous System Depressants

All Drugs and Chemicals

Anti-Infective Agents

Bupivacaine

Ethanol

Anti-Infective Agents, Local

Radiofrequency ablation of the coeliac plexus

* coeliac plexus is identified and punctured
* Injection of 10 mL of .25% bupivacaine, followed by 10 mL of 98% dehydrated alcohol.

98% dehydrated alcohol

* 10W-30W RFA will be applied unilaterally or bilaterally depends on individual anatomical characteristics for 10-50s
* Complete ablation of coeliac plexus nervous tissue is confirmed by appearance of air-bubble ultrasound scan

19G EUSRA needle, Taewoong Medical, Korea

Wan Yee Chiu, BISC

Ka Wing Ma, MBBS, MS

Many cancer patients suffer from intractable pain and which is often suboptimally controlled by even strong opioid analgesics. Coeliac plexus neurolysis (CPN) is procedure which intended to permanently destroy the nociceptive pathway that transmits the pain caused by the tumour. It can be with different approaches, such as percutaneously guided by fluoroscopy, echo-endoscopically or surgically with endoscopic approach being the more popular one in many centers equipped with echo-endoscopic services. The effect of CPN has been well established by some retrospective series. The overall response rate to CPN ranges from 70-90%, however, the analgesic effect is limited and up to roughly around 3 months. It is believed that the short-lasting analgesic effect is related to incomplete neurolysis by absolute alcohol injection.

Recently, radiofrequency ablation (RFA) of coeliac plexus has been introduced as another mode of CPN. So far, only one small single center randomized controlled trial (RCT) suggesting superior performance in favour to CPN using RFA. This result has to be validated and by a RCT with larger sample size. In addition, data concerning the quality of life (QOL) improvement and cost-effectiveness need to be further elucidated. Therefore, the aim of this study is to perform a RCT to look into these issues.

The aim of this study is to compare the efficacy of EUS-guided CPN versus radiofrequency ablation in patients with pain related to pancreatic cancer. By performing a randomized controlled trial, the clinical outcomes and cost-effectiveness of this new RFA treatment approach can be evaluated.

EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy

Endoscopic Ultrasound Guided Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Intractable Pain Due to Malignancy A Randomized Controlled Study

Pain score at 4 weeks after procedure (by VAS score)

Decrease of pain level by 30% from pre-procedural baseline

Time from injection of pre-medication to procedure last observation recording at the procedure suite

The University of Hong Kong

Clinical Assistant Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy	NCT04809935	Cancer of Pancr... Pancreatic Neop... Pain Cancer-Associat... Pain Management	98% dehydrated ... 19G EUSRA needl...	18 Years -	The University of Hong Kong
EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy	NCT04809935	Cancer of Pancr... Pancreatic Neop... Pain Cancer-Associat... Pain Management	98% dehydrated ... 19G EUSRA needl...	18 Years -	The University of Hong Kong

Spots Global Cancer Trial Database for 19g eusra needle, taewoong medical, korea